Tirzepatide 0.5 mg: clearing up a very common dose question

Step 1, understanding where the 0.5 mg figure comes from

Semaglutide, sold as Wegovy for weight management and Ozempic for type 2 diabetes, follows a gradual titration that passes through 0.25 mg and 0.5 mg in its early weeks. That schedule is widely discussed online, and because semaglutide and tirzepatide are both injectable GLP-1-related medicines used for weight loss, their dosing details get blurred together. The result is a steady stream of searches for tirzepatide 0.5 mg, a dose that simply isn't part of the medicine's licensed schedule in the UK.

Tirzepatide is a dual agonist, activating both GIP and GLP-1 receptors; semaglutide targets GLP-1 alone. The two medicines were built differently, trialled at different dose ranges, and approved at different strengths. Treating their schedules as interchangeable is a bit like applying the instructions for one antibiotic to a different one entirely. The NHS medicines page for tirzepatide sets out the licensed doses clearly, and it's worth reading if you're trying to understand where you'd start and what comes next.

If you've been told by a previous provider that you were on 0.5 mg of tirzepatide, it's worth double-checking your prescription records. There's a reasonable chance the medicine was actually 2.5 mg tirzepatide, the starter strength that exists specifically to reduce the nausea and gastrointestinal discomfort that can come with beginning treatment.

Step 2, how tirzepatide's licensed schedule is actually structured

Mounjaro's titration begins at 2.5 mg for the first four weeks. That first pen's job is adjustment, not weight loss in itself; the dose is low enough that most people tolerate the medicine well while their body gets used to slowed gastric emptying and reduced appetite signals. After that, the prescriber typically increases to 5 mg, then to 7.5 mg and beyond, in roughly four-week steps, based on how you're responding and tolerating each level.

You can read more about the step from starter to therapeutic dose on our 5 mg tirzepatide page, which covers what changes when the dose moves up. The maximum licensed dose is 15 mg. Not everyone reaches it; many people find meaningful results at lower maintenance doses, and a prescriber will weigh efficacy against tolerability before recommending any increase.

Each Mounjaro KwikPen contains four weekly doses of the same strength, so one pen covers a full four-week period. If you're curious about the format you'd actually receive (it arrives by tracked DPD delivery the next working day, in a plain unbranded box, refrigerated with a cool pack) that's what to expect once your prescription is approved. Storage is in the fridge at 2–8°C; the SmPC published on the electronic Medicines Compendium (eMC) gives the exact guidance on temperature windows.

Step 3, what to do if you're genuinely unsure which medicine or dose you need

If you've been researching tirzepatide and keep landing on 0.5 mg figures, the most useful thing is to separate the two medicines clearly before deciding anything else. Our Mounjaro overview page covers how tirzepatide works, who it's licensed for, and the full dose range. If you've already been on treatment elsewhere and want to continue or adjust, a prescriber will want to see evidence of your current dose before any decision is made, that's standard clinical practice, not a hurdle.

Eligibility for Mounjaro under its UK licence covers adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI is one part of the picture; your prescriber reviews the whole clinical context. Tirzepatide is a prescription-only medicine and NICE recommends it for weight management in line with specific criteria set out in their technology appraisal TA1026.

Common side effects across the dose range are gastrointestinal: nausea, loose stools, constipation, bloating and reflux are the most frequently reported, generally peaking after starting or a dose increase and settling within a couple of weeks for most people. Serious events are uncommon but include acute pancreatitis, the MHRA flagged this in a Drug Safety Update and advises seeking prompt medical help for severe stomach pain that spreads to the back. If you want to understand how side effects tend to differ as the dose moves up, our pages on 0.5 mg tirzepatide and 1 mg tirzepatide explain how those lower reference points compare to the licensed strengths used in the UK. More detail on managing side effects is on our FAQs page.

The question of cost often comes up alongside dose questions. Treatment price varies by dose and provider; context on what private tirzepatide typically costs in the UK, and what a legitimate price should include, is covered on our Mounjaro access and cost page. The short version: a real prescription must include a clinical assessment, that's not optional, it's the law.

If you'd like a prescriber to review whether tirzepatide is right for you, check your eligibility through a free consultation with the nume clinical team.